Natalizumab discontinuation/interruption: relapse risk, poor tolerability


REPORT FROM THE 63rd ANNUAL MEETING OF THE AMERICAN ACADEMY OF NEUROLOGY (AAN), HONOLULU, HAWAII, APRIL 9-16, 2011 – A retrospective analysis of patients who discontinued natalizumab has concluded that there is an elevated risk of increased disease activity and worsening disability if the drug is stopped (Kelly et al. AAN 2011; abstract P01.197).

It takes 30 seconds

Recommend to a Colleague

Related Posts

Go back to home page